The biopharmaceutical industry has long faced hurdles integrating advanced manufacturing technologies (AMTs) into commercial biomanufacturing. Despite the clear benefits of AMTs, including enhanced efficiency, scalability, and product quality, adoption rates remain sluggish. This article seeks to
The biopharmaceutical industry has been growing steadily, driven by the development of new modalities and biomanufacturing technologies. Traditional bioprocessing methods, while effective, are facing significant challenges as the complexity and diversity of biopharma pipelines increase. This has
In an exciting development, Scorpius Holdings has been selected as a member of the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV). This collaboration is expected to significantly enhance BARDA’s mission to accelerate the development of med
The ongoing evolution and novel advancements in filtration technology are essential for biologics manufacturing, as the complexity and size of therapeutic modalities increase. This evolution has introduced new challenges that require efficient and effective filtration systems to ensure the
Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,
